Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics.

Saved in:
Bibliographic Details
Title: Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics.
Authors: Donati M; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. monia.donati5@unibo.it., Cancellerini C; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Giunchi V; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Rossi S; IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica-Rete Metropolitana (NeuroMet), Bologna, Italy., Massari F; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Gelsomino F; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Poluzzi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Raschi E; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Source: Targeted oncology [Target Oncol] 2026 May; Vol. 21 (3), pp. 433-445. Date of Electronic Publication: 2026 May 06.
Publication Type: Journal Article
Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Be the first to leave a comment!
You must be logged in first